{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:42:55Z","timestamp":1786203775631,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00520-026-11045-7","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:39:54Z","timestamp":1785335994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Febrile neutropenia in patients treated with chemotherapy\/immune checkpoint inhibition: a MASCC consensus statement"],"prefix":"10.1007","volume":"34","author":[{"given":"Tim","family":"Cooksley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Font","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Thursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Falandry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"31","key":"11045_CR1","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","volume":"34","author":"M Reck","year":"2016","unstructured":"Reck M, Luft A, Szczesna A, Havel L, Kim SW et al (2016) Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34(31):3740\u20133748","journal-title":"J Clin Oncol"},{"key":"11045_CR2","doi-asserted-by":"crossref","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, KEYNOTE-021 investigators et al (2016) Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17(11):1497\u20131508","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"11045_CR3","doi-asserted-by":"crossref","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, KEYNOTE-966 Investigators et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401(10391):1853\u20131865","DOI":"10.1016\/S0140-6736(23)00727-4"},{"key":"11045_CR4","doi-asserted-by":"crossref","unstructured":"Chung HC, Ros W, Delord JP, Perets R et al (2019) Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 37(17):1470\u20131478","DOI":"10.1200\/JCO.18.01265"},{"issue":"17","key":"11045_CR5","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M et al (2024) First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial. J Clin Oncol 42(17):2012\u20132020","journal-title":"J Clin Oncol"},{"key":"11045_CR6","doi-asserted-by":"crossref","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, KEYNOTE-355 Investigators et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217\u2013226","DOI":"10.1056\/NEJMoa2202809"},{"key":"11045_CR7","volume-title":"SIGN 50. A guideline developer\u2019s handbook","author":"Scottish Intercollegiate Guidelines Network","year":"2008","unstructured":"Scottish Intercollegiate Guidelines Network (2008) SIGN 50. A guideline developer\u2019s handbook. SIGN, Edinburgh"},{"key":"11045_CR8","doi-asserted-by":"crossref","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT (2040) Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open 4(4):e214708","DOI":"10.1001\/jamanetworkopen.2021.4708"},{"key":"11045_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s44201-021-00001-2","volume":"1","author":"KH Todd","year":"2022","unstructured":"Todd KH (2022) Emergency cancer care: inaugural editorial. Emerg Cancer Care 1:1","journal-title":"Emerg Cancer Care"},{"issue":"1","key":"11045_CR10","first-page":"3","volume":"25","author":"T Cooksley","year":"2017","unstructured":"Cooksley T, Rice T (2017) Emergency oncology: development, current position and future direction in the US and UK. Support Care Cancer 25(1):3\u20137","journal-title":"Support Care Cancer"},{"issue":"3","key":"11045_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09245-8","volume":"33","author":"AL Hurley-Wallace","year":"2025","unstructured":"Hurley-Wallace AL, Defty J, Richardson A, Wagland R (2025) Mixed methods scoping review of patients\u2019 experiences of urgent and emergency cancer care. Support Care Cancer 33(3)","journal-title":"Support Care Cancer"},{"issue":"9","key":"11045_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/acem.14671","volume":"30","author":"S Kang","year":"2023","unstructured":"Kang S, McLeod SL, Walsh C, Grewal K (2023) Patient outcomes associated with cancer diagnosis through the emergency department: a systematic review. Acad Emerg Med 30(9):955\u2013962","journal-title":"Acad Emerg Med"},{"issue":"10","key":"11045_CR13","doi-asserted-by":"publisher","first-page":"e172450","DOI":"10.1001\/jamaoncol.2017.2450","volume":"3","author":"DR Rivera","year":"2017","unstructured":"Rivera DR, Gallicchio L, Brown J et al (2017) Trends in adult cancer-related emergency department utilization: an analysis of data from the nationwide emergency department sample. JAMA Oncol 3(10):e172450","journal-title":"JAMA Oncol"},{"issue":"11","key":"11045_CR14","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.ajem.2018.03.025","volume":"36","author":"J Hsu","year":"2018","unstructured":"Hsu J, Donnelly JP, Moore JX et al (2018) National characteristics of emergency department visits by patients with cancer in the United States. Am J Emerg Med 36(11):2038\u20132043","journal-title":"Am J Emerg Med"},{"issue":"11","key":"11045_CR15","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/jamainternmed.2016.5974","volume":"176","author":"J Conley","year":"2016","unstructured":"Conley J, O\u2019Brien CW, Leff BA et al (2016) Alternative strategies to inpatient hospitalization for inpatient conditions: a systematic review. JAMA Intern Med 176(11):1693\u20131702","journal-title":"JAMA Intern Med"},{"key":"11045_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p343","volume":"380","author":"D Lasserson","year":"2023","unstructured":"Lasserson D, Cooksley T (2023) Virtual wards: urgent care policy must follow the evidence. BMJ 380","journal-title":"BMJ"},{"issue":"5","key":"11045_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00520-015-3006-0","volume":"24","author":"C Font","year":"2016","unstructured":"Font C, Fernandez-Avil\u00e9s F, Calderon C et al (2016) Home management of acute medical complications in cancer patients. Support Care Cancer 24(5):2129\u20132137","journal-title":"Support Care Cancer"},{"issue":"1","key":"11045_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13436","volume":"74","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Marshall W, Ahn S et al (2020) Ambulatory emergency oncology: a key tenet for future emergency oncology care. Int J Clin Pract 74(1)","journal-title":"Int J Clin Pract"},{"issue":"22","key":"11045_CR19","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078\u20132092","journal-title":"N Engl J Med"},{"key":"11045_CR20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","volume":"130","author":"T Cooksley","year":"2020","unstructured":"Cooksley T, Gupta A, Al-Sayed T, Lorigan P (2020) Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer 130:193\u2013197","journal-title":"Eur J Cancer"},{"key":"11045_CR21","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","volume":"21","author":"J Klastersky","year":"2013","unstructured":"Klastersky J, Paesmans M (2013) The Multinational Association for Supportive Care in Cancer (MASCC) risk score: 10 years of use for identifying low risk neutropenic cancer patients. Support Care Cancer 21:1487\u20131495","journal-title":"Support Care Cancer"},{"key":"11045_CR22","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1093\/annonc\/mdq745","volume":"22","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Ethier M, Alibhal S et al (2011) Outpatient management of cancer patients with febrile neutropenia: a systematic review and meta-analysis. Ann Oncol 22:2358\u20132365","journal-title":"Ann Oncol"},{"issue":"4","key":"11045_CR23","doi-asserted-by":"publisher","first-page":"178","DOI":"10.52964\/AMJA.0529","volume":"14","author":"T Cooksley","year":"2015","unstructured":"Cooksley T, Holland M, Klastersky J (2015) Ambulatory outpatient management of patients with low risk febrile neutropaenia. Acute Med 14(4):178\u2013181","journal-title":"Acute Med"},{"key":"11045_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00520-010-0925-7","volume":"19","author":"M Paesmans","year":"2011","unstructured":"Paesmans M, Klastersky J, Maertens J et al (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19:1001\u20131008","journal-title":"Support Care Cancer"},{"issue":"12","key":"11045_CR25","first-page":"665","volume":"31","author":"E Forcano-Queralt","year":"2023","unstructured":"Forcano-Queralt E, Lemes-Quintana C, Orozco-Beltr\u00e1n D (2023) Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systemat Rev Supp Care Cancer 31(12):665","journal-title":"Systemat Rev Supp Care Cancer"},{"key":"11045_CR26","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein E et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038\u20133051","journal-title":"J Clin Oncol"},{"issue":"5","key":"11045_CR27","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00520-017-3985-0","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Rice TW, Yeung SJ, Cooksley T (2018) Comparison of the MASCC and CISNE scores for identifying low risk neutropenic fever patients: analysis of data from three emergency departments in cancer centers in three continents. Support Care Cancer 26(5):1465\u20131470","journal-title":"Support Care Cancer"},{"issue":"3","key":"11045_CR28","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jemermed.2019.09.032","volume":"58","author":"W Marshall","year":"2020","unstructured":"Marshall W, Campbell G, Knight T et al (2020) Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK cancer center. J Emerg Med 58(3):444\u2013448","journal-title":"J Emerg Med"},{"issue":"3","key":"11045_CR29","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00520-017-3921-3","volume":"26","author":"BW Teh","year":"2018","unstructured":"Teh BW, Brown C, Joyce T et al (2018) Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer 26(3):997\u20131003","journal-title":"Support Care Cancer"},{"issue":"9","key":"11045_CR30","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00520-018-4194-1","volume":"26","author":"T Cooksley","year":"2018","unstructured":"Cooksley T, Campbell G, Al-Sayed T et al (2018) A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) Clinic. Support Care Cancer 26(9):2937\u20132940","journal-title":"Support Care Cancer"},{"issue":"1","key":"11045_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.52964\/AMJA.0742","volume":"18","author":"C Brunner","year":"2019","unstructured":"Brunner C, Botten J, Wennike N et al (2019) Early supported discharge for patients with febrile neutropenia: experience from a large district hospital in the UK. Acute Med 18(1):13\u201318","journal-title":"Acute Med"},{"key":"11045_CR32","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1007\/s00520-018-4157-6","volume":"26","author":"FLM Ying","year":"2018","unstructured":"Ying FLM, Ping MCY, Tong M et al (2018) A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia. Support Care Cancer 26:3039\u20133045","journal-title":"Support Care Cancer"},{"issue":"2","key":"11045_CR33","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s00520-020-05906-y","volume":"29","author":"T Cooksley","year":"2021","unstructured":"Cooksley T, Font C, Scotte F et al (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 29(2):1129\u20131138","journal-title":"Support Care Cancer"},{"key":"11045_CR34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1200\/JCO.2012.45.8109","volume":"31","author":"W Kern","year":"2013","unstructured":"Kern W, Marchetti O, Drgona L et al (2013) Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicentre trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin\/clavulanic acid combination therapy \u2013 EORTC Infectious Diseases Group trial XV. J Clin Oncol 31:1149\u20131156","journal-title":"J Clin Oncol"},{"key":"11045_CR35","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/bjc.2011.101","volume":"104","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Amir E, Alibhai S et al (2011) Cost-effectiveness of outpatient treatment for febrile neutropenia in adult cancer patients. B J Cancer 104:1377\u20131383","journal-title":"B J Cancer"},{"key":"11045_CR36","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00520-012-1397-8","volume":"20","author":"O Teuffel","year":"2012","unstructured":"Teuffel O, Cheng S, Ethier M et al (2012) Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 20:2755\u20132764","journal-title":"Support Care Cancer"},{"issue":"2","key":"11045_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14740\/jh1090","volume":"12","author":"T Ohashi","year":"2023","unstructured":"Ohashi T, Takase-Minegishi K, Maeda A, Hamada N et al (2023) Incidence and risk of hematological adverse events associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis. J Hematol 12(2):66\u201374","journal-title":"J Hematol"},{"issue":"2","key":"11045_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09168-4","volume":"33","author":"JMJ Weaver","year":"2025","unstructured":"Weaver JMJ, Nagy B, Wilson C, Lewis A, Armstrong A, Cooksley T (2025) Low-risk febrile neutropenia: does combined chemotherapy\/immune checkpoint inhibitor necessitate a change in approach? Support Care Cancer 33(2)","journal-title":"Support Care Cancer"},{"key":"11045_CR39","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111\u2013v118","journal-title":"Ann Oncol"},{"issue":"3","key":"11045_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/17512433.2021.1884067","volume":"14","author":"BL Rapoport","year":"2021","unstructured":"Rapoport BL, Cooksley T, Johnson DB et al (2021) Treatment of infections in cancer patients: an update from the neutropenia, infection and myelosuppression study group of the Multinational Association for Supportive Care in Cancer (MASCC). Expert Rev Clin Pharmacol 14(3):295\u2013313","journal-title":"Expert Rev Clin Pharmacol"},{"key":"11045_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1585","volume":"353","author":"JE Gotts","year":"2016","unstructured":"Gotts JE, Matthay MA (2016) Sepsis: pathophysiology and clinical management. BMJ 353","journal-title":"BMJ"},{"key":"11045_CR42","doi-asserted-by":"crossref","unstructured":"Higham CE, Olsson-Brown A, Carroll P, Society for Endocrinology Clinical Committee et al (2018) Society for Endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1\u2013G7","DOI":"10.1530\/EC-18-0068"},{"key":"11045_CR43","unstructured":"Cooksley T, Marshall E, Jones P et al; Acute Oncology Neutropenia Working Party. Ambulatory pathway for oncology patients presenting with low risk febrile neutropenia. 2020. Microsoft Word - Final Ambulatory LRFN Pathway 11 2020 docx.docx"},{"issue":"Suppl 7","key":"11045_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/imj.70251","volume":"55","author":"JSK Teh","year":"2025","unstructured":"Teh JSK, Singh N, Lambros B, Yong MK, Butters C, Routledge D, Underhill C, Kong DDC, Weinkove R, Padhye B, Rockliff B, Worth LJ, Haeusler GM, Australasian Neutropenic Fever Guidelines Steering Committee (2025) Consensus guidelines for ambulatory care for neutropenic fever. Intern Med J 55(Suppl 7):95\u2013114","journal-title":"Intern Med J"},{"key":"11045_CR45","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","volume":"24","author":"J Klastersky","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129\u20134134","journal-title":"J Clin Oncol"},{"key":"11045_CR46","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.breast.2025.104536","volume":"83","author":"T Cooksley","year":"2025","unstructured":"Cooksley T, Adam S, Nagy B, Raby S, Armstrong A, Weaver JM (2025) Acute presentations in neoadjuvant chemotherapy\/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data. Breast 83:104536","journal-title":"Breast"},{"issue":"12","key":"11045_CR47","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s00520-020-05727-z","volume":"28","author":"BL Rapoport","year":"2020","unstructured":"Rapoport BL, Anderson R, Cooksley T, Johnson DB (2020) MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer 28(12):6107\u20136110","journal-title":"Support Care Cancer"},{"issue":"25","key":"11045_CR48","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.2020009016","volume":"139","author":"MH Kroll","year":"2022","unstructured":"Kroll MH, Rojas-Hernandez C, Yee C (2022) Hematologic complications of immune checkpoint inhibitors. Blood 139(25):3594\u20133604","journal-title":"Blood"},{"issue":"1","key":"11045_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0648-3","volume":"7","author":"AR Naqash","year":"2019","unstructured":"Naqash AR, Appah E, Yang LV, Muzaffar M et al (2019) Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition. J Immunother Cancer 7(1)","journal-title":"J Immunother Cancer"},{"issue":"20","key":"11045_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205030","volume":"14","author":"M Martin","year":"2022","unstructured":"Martin M, Nguyen HM, Beuvon C, Bene J et al (2022) Immune checkpoint inhibitor-related cytopenias: about 68 cases from the French Pharmacovigilance Database. Cancers (Basel) 14(20)","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11045_CR51","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J et al (2019) Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol 6(1):e48\u2013e57","journal-title":"Lancet Haematol"},{"issue":"8","key":"11045_CR52","doi-asserted-by":"publisher","first-page":"e2424793","DOI":"10.1001\/jamanetworkopen.2024.24793","volume":"7","author":"AK Balitsky","year":"2024","unstructured":"Balitsky AK, Rayner D, Britto J et al (2024) Patient-reported outcome measures in cancer care: an updated systematic review and meta-analysis. JAMA Netw Open 7(8):e2424793","journal-title":"JAMA Netw Open"},{"issue":"3","key":"11045_CR53","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00520-019-04945-4","volume":"28","author":"J Osborn","year":"2020","unstructured":"Osborn J, Ajakaiye A, Cooksley T, Subbe CP (2020) Do mHealth applications improve clinical outcomes of patients with cancer? A critical appraisal of the peer-reviewed literature. Support Care Cancer 28(3):1469\u20131479","journal-title":"Support Care Cancer"},{"issue":"6","key":"11045_CR54","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","volume":"28","author":"O Mir","year":"2022","unstructured":"Mir O, Ferrua M, Fourcade A, Mathivon D, Duflot-Boukobza A et al (2022) Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med 28(6):1224\u20131231","journal-title":"Nat Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11045-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11045-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:55:21Z","timestamp":1786200921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-11045-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11045"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11045-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"813"}}